Autel to Showcase Breakthrough EV Charging Innovations at ICNC23
29.8.2023 12:21:00 EEST | Business Wire | Press release
Autel Energy, a leading provider of innovative EV charging solutions, is pleased to announce its participation in the highly-anticipated Intercharge Network Conference 2023 (ICNC23) to be held on August 29-31, 2023, in Berlin. Ting Cai, CEO of Autel Europe, is set to captivate the audience with an insightful speech on the future of EV charging. Autel's hallmark innovation, the MaxiCharger DC Compact, will take center stage as it makes a live demonstration at the Plug&Charge Showcase Zone to showcase its seamless charging process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828771064/en/
Complete MaxiCharger Lineup Unveiled at ICNC23 and IAA MOBILITY 2023 (Graphic: Business Wire)
ICNC23 is renowned for bringing together top industry professionals, experts, and stakeholders in the electric vehicle charging infrastructure domain. Ting Cai’s speech and Autel’s charging capabilities of its products will provide attendees with an exclusive opportunity to experience first-hand the cutting-edge technology that Autel Energy has brought to the market.
Autel MaxiCharger series offer a revolutionary charging solution that has transformed the charging experience for electric vehicle owners. With its high-speed charging capabilities, intuitive user interface, and compatibility with various electric vehicle models, Autel has earned its reputation as an indispensable tool for EV owners. Notably, Autel Energy has been officially checked and validated by Hubject, making its way into the Plug&Charge ecosystem. At ICNC23, Autel will bring its MaxiCharger DC Compact to demonstrate the charging process at the Plug&Charge Showcase Zone, which will impeccably showcase its exceptional features, emphasizing its role in providing a seamless and efficient charging process for electric vehicles.
Following the ICNC23, Autel Energy is excited to continue its engagement with the electric vehicle community at IAA MOBILITY 2023 (International Motor Show Germany) to take place on September 5-10, 2023, in Munich. During this period, Autel will embark on a roadshow, with its event vehicles journeying from ICNC in Berlin all the way to IAA MOBILITY in Munich and ultimately welcoming visitors at booth C2 A31.
"We are delighted to be part of ICNC23 and IAA MOBILITY 2023, where we can showcase the capabilities of Autel’s EV chargers and its seamless integration with various EV models," said Ting Cai, CEO of Autel Europe. "As the EV market continues to grow, Autel Energy remains committed to delivering cutting-edge charging solutions that enhance the driving experience for EV owners worldwide."
Visitors attending ICNC23 and IAA MOBILITY will have the exclusive opportunity to explore the charging process of the demonstration EV by Autel Energy's comprehensive array of EV charging products. Autel Energy's team of experts will be available at the event to engage with visitors, share insights, and discuss the transformative potential of their cutting-edge charging solutions.
For more information about Autel Energy and its EV charging solutions, please visit: https://autelenergy.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828771064/en/
Contact information
Jiaqi Liu
Email:jiaqi.liu@autel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom